Shire Plc American Depositary Shares (SHPG) 253.58 $SHPG
Hedge fund honcho eyes Biogen patent covering top-selling Tecfidera
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:04PM CDT
BIIB: 423.57 (+1.46), SHPG: 253.58 (+3.70), ACOR: 33.34 (-1.33)
Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 12:18PM CDT
Abbott Laboratories (ABT) reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents.
ABT: 48.35 (+1.23), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), MYL: 72.40 (-1.67)
3 Large-Cap Pharmaceutical Companies to Invest in Right Now
at The Street - Wed Apr 22, 8:23AM CDT
Pharmaceutical companies can be a huge risk for investors -- but if the risks pay off, the rewards can be huge.
NVO: 56.37 (-0.17), SHPG: 253.58 (+3.70), RDY: 56.58 (+0.30)
Gilead Sciences Vs. AbbVie: Which Is A Better Buy?
Mycroft - at Seeking Alpha - Wed Apr 22, 7:49AM CDT
JNJ: 100.43 (+0.13), ABT: 48.35 (+1.23), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91)
Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:07PM CDT
Seattle Genetics, Inc.'s (SGEN) supplemental BLA for Adcetris has been accepted by the FDA for priority review as consolidation therapy in the post-transplant setting.
SGEN: 36.92 (-0.32), SHPG: 253.58 (+3.70), HZNP: 30.96 (+0.10), BMY: 66.60 (-0.21)
Merck KGaA-Pfizer Start First Cancer Registration Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:50PM CDT
Merck KGaA (MKGAF) and Pfizer Inc. (PFE) announced the commencement of a phase III study on avelumab in comparison with Taxotere for non-small cell lung cancer.
SHPG: 253.58 (+3.70), PFE: 34.93 (+0.04), HZNP: 30.96 (+0.10)
Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 11:48AM CDT
Ampio Pharmaceuticals, Inc. (AMPE) announced disappointing results from the multiple injection STRIDE study AP008 on pipeline candidate Ampion.
VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), ARQL: 2.11 (-0.03), AMPE: 2.89 (+0.20)
Genzyme starts mid-stage trial of oral Fabry disease therapy
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 10:34AM CDT
SHPG: 253.58 (+3.70), PLX: 2.08 (+0.02), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
This New Hedge Fund Strategy Just Might Be Crazy Enough To Work
Matthew Frankel, The Motley Fool - Motley Fool - Sun Apr 19, 1:07PM CDT
Hedge funds use a lot of strategies to make money, but one manager is doing something we've never seen before in order to make a profit -- challenging a company's patents and shorting its stock simultaneously. How exactly does it work, and will it...
SHPG: 253.58 (+3.70), JAZZ: 186.13 (-0.41), ACOR: 33.34 (-1.33)
Will This Hedge Fund Manager Bring Down Your Biotech Stocks?
Selena Maranjian, The Motley Fool - Motley Fool - Sun Apr 19, 12:01PM CDT
Hedge-fund manager Kyle Bass. Image: Insider Monkey Many hedge-fund managers are "activist" ones. They load up on stock in particular companies until they have so many shares that they can put pressure on management to take actions they...
SHPG: 253.58 (+3.70), JAZZ: 186.13 (-0.41), ACOR: 33.34 (-1.33)
4 Big Biopharma Deals We Might See In 2015
Sy Mukherjee - Seeking Alpha - Thu Apr 16, 1:29PM CDT
In 2000, UK-based Glaxo Wellcome joined forces with SmithKline Beecham in a $74 billion merger that birthed the global pharma giant GlaxoSmithKline (NYSE: GSK ). It was, far and away, the biggest biopharma deal of the year. What a difference 14...
BMRN: 121.08 (-0.16), PCYC: 256.98 (-0.77), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72), SGEN: 36.92 (-0.32), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), AZN: 73.35 (+0.65), JAZZ: 186.13 (-0.41), MRK: 57.69 (+0.03), ABBV: 64.52 (+0.91)
Goldman's Monster Q1 Spurred By Megadeals, Volatility
at Investor's Business Daily - Thu Apr 16, 10:32AM CDT
Goldman Sachs (GS) crushed Wall Street's first-quarter expectations, as stock market volatility fueled trading revenue and a string of megadeals boosted advisory fees. The investment banking giant earned $5.94 a share, up 47.8% from a year earlier...
GS: 198.32 (+1.48), JPM: 62.94 (+0.63), C: 53.10 (+0.62), SHPG: 253.58 (+3.70), BAC: 15.74 (+0.24), WFC: 54.67 (+0.39), MS: 37.20 (+0.45)
Cardiomyopathy Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 15, 1:20PM CDT
The report "Cardiomyopathy - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cardiomyopathy. Cardiomyopathy, any cardiac disease process that results in heart failure due to a decrease in the pumping power of the heart or due to an impairment in the filling of the cardiac chambers. Types of Cardiomyopathy are ischemic, dilated, hypertrophic and restrictive Cardiomyopathy. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cardiomyopat...eport.html .
GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), CLDN: 13.59 (-2.77), NVS: 103.45 (-0.62)
Analyzing The FTSE 100 For Opportunities
Nick Mackintosh - at Seeking Alpha - Mon Apr 13, 10:05PM CDT
BTI: 112.59 (+0.32), ARMH: 54.07 (+0.47), SHPG: 253.58 (+3.70)
Goldman's Q1 Seen Lifted By Gyrating Stocks, Big M&A
at Investor's Business Daily - Mon Apr 13, 4:26PM CDT
The volatile stock market and heavier trading volumes should translate into a good first quarter for Goldman Sachs (GS), which also should receive a boost from its financial advisory unit thanks to Q1's strong M&A activity. When it reports results on...
GS: 198.32 (+1.48), JPM: 62.94 (+0.63), SHPG: 253.58 (+3.70), MS: 37.20 (+0.45)
CNS Therapeutics - Global Strategic Business Report 2015-2020
M2 - Mon Apr 13, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ht282w/cns_therapeutics) has announced the addition of the "CNS Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 145 companies including many key and niche players such as: - AbbVie Inc. (USA) - Actavis Plc. (Ireland) - Alkermes Plc. (Ireland) - Amneal Pharmaceuticals, LLC (USA) - Aspen Pharmacare Holdings Limited (Australia) - AstraZeneca Plc (UK) - BIAL Group (Portugal) - Boehringer Ingelheim GmbH (Germany) - Bristol-Myers Squibb (USA) - Dainippon Sumitomo Pharma Co., Ltd. (Japan) - Eisai Co., Ltd. (Japan) - Eli Lilly and Co. (USA) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fabre-Kramer Pharmaceuticals, Inc. (USA) - GlaxoSmithKline (UK) - H. Lundbeck A/S (Denmark) - Johnson & Johnson (USA) - Janssen Pharmaceuticals, Inc. (USA) - Merck & Co., Inc. (USA) - Neurocrine Biosciences, Inc. (USA) - Novartis AG (Switzerland) - Otsuka Pharmaceutical Co., Ltd. (Japan) - Pfizer, Inc. (USA) - Sanofi S.A (France) - Shire Plc (UK) - Sunovion Pharmaceuticals, Inc. (USA) - Takeda Pharmaceutical Co., Ltd. (Japan) - Teva Pharmaceutical Industries Ltd. (Israel) - UCB Group (Belgium) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. NOTEWORTHY MARKET TRENDS, GROWTH DRIVERS & ISSUES 3. MARKET ANALYSIS BY THERAPEUTIC CATEGORIES 4. PRODUCT OVERVIEW 5. PRODUCT INTRODUCTIONS/INNOVATIONS & R&D BREAKTHROUGHS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 145 (including Divisions/Subsidiaries - 172) - The United States (69) - Canada (11) - Japan (14) - Europe (47) - - France (4) - - Germany (9) - - The United Kingdom (11) - - Italy (1) - - Rest of Europe (22) - Asia-Pacific (Excluding Japan) (23) - Middle East (7) - Africa (1) For more information visit http://www.researchandmarkets.com/research/ht...erapeutics
PFE: 34.93 (+0.04), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), ALKS: 62.60 (-0.24), JNJ: 100.43 (+0.13), NBIX: 43.23 (-0.43), SHPG: 253.58 (+3.70), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15), ABBV: 64.52 (+0.91), NVS: 103.45 (-0.62)
Shire's SHP625 Fails in Phase II, FDA Accepts Lifitegrast NDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 4:26PM CDT
Shire plc (SHPG) announced disappointing results from the phase II trial IMAGO on pipeline candidate SHP625 (formerly LUM001).
ACT: 295.22 (+0.69), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), ARQL: 2.11 (-0.03)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 423.57 (+1.46), SPHS: 0.82 (+0.01), ADMS: 17.62 (-0.21), TKMR: 18.38 (-0.14), CBYL: 7.02 (-0.38), HPTX: 45.96 (-0.18), QURE: 26.15 (-1.44), SHPG: 253.58 (+3.70), SRPT: 13.52 (+0.04), HZNP: 30.96 (+0.10), GALE: 1.39 (unch), JUNO: 55.72 (-0.68), ABBV: 64.52 (+0.91), CBMG: 32.14 (+2.21), ARNA: 4.47 (+0.01), EXEL: 3.12 (+0.05), ADXS: 22.18 (+0.10), PTLA: 38.48 (-0.47), BMY: 66.60 (-0.21), OCUL: 25.90 (-0.05), NVO: 56.37 (-0.17), DVA: 83.22 (+0.10), HALO: 16.03 (+0.15), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), ALXN: 188.19 (+1.41), NVS: 103.45 (-0.62)
Critical Alerts For GoPro, Shire, Isis Pharmaceuticals, Whiting Petroleum and athenahealth Released By InvestorsObserver
PR Newswire - Fri Apr 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, SHPG, ISIS, WLL and ATHN.
GPRO: 46.25 (+1.94), WLL: 36.12 (+1.16), ISIS: 66.26 (-0.03), SHPG: 253.58 (+3.70), ATHN: 120.16 (-1.35)
Hedge fund honcho eyes Biogen patent covering top-selling Tecfidera
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:04PM CDT
BIIB: 423.57 (+1.46), SHPG: 253.58 (+3.70), ACOR: 33.34 (-1.33)
Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 12:18PM CDT
Abbott Laboratories (ABT) reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents.
ABT: 48.35 (+1.23), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), MYL: 72.40 (-1.67)
3 Large-Cap Pharmaceutical Companies to Invest in Right Now
at The Street - Wed Apr 22, 8:23AM CDT
Pharmaceutical companies can be a huge risk for investors -- but if the risks pay off, the rewards can be huge.
NVO: 56.37 (-0.17), SHPG: 253.58 (+3.70), RDY: 56.58 (+0.30)
Gilead Sciences Vs. AbbVie: Which Is A Better Buy?
Mycroft - at Seeking Alpha - Wed Apr 22, 7:49AM CDT
JNJ: 100.43 (+0.13), ABT: 48.35 (+1.23), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91)
Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:07PM CDT
Seattle Genetics, Inc.'s (SGEN) supplemental BLA for Adcetris has been accepted by the FDA for priority review as consolidation therapy in the post-transplant setting.
SGEN: 36.92 (-0.32), SHPG: 253.58 (+3.70), HZNP: 30.96 (+0.10), BMY: 66.60 (-0.21)
Merck KGaA-Pfizer Start First Cancer Registration Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:50PM CDT
Merck KGaA (MKGAF) and Pfizer Inc. (PFE) announced the commencement of a phase III study on avelumab in comparison with Taxotere for non-small cell lung cancer.
SHPG: 253.58 (+3.70), PFE: 34.93 (+0.04), HZNP: 30.96 (+0.10)
Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 11:48AM CDT
Ampio Pharmaceuticals, Inc. (AMPE) announced disappointing results from the multiple injection STRIDE study AP008 on pipeline candidate Ampion.
VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), ARQL: 2.11 (-0.03), AMPE: 2.89 (+0.20)
Genzyme starts mid-stage trial of oral Fabry disease therapy
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 10:34AM CDT
SHPG: 253.58 (+3.70), PLX: 2.08 (+0.02), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
This New Hedge Fund Strategy Just Might Be Crazy Enough To Work
Matthew Frankel, The Motley Fool - Motley Fool - Sun Apr 19, 1:07PM CDT
Hedge funds use a lot of strategies to make money, but one manager is doing something we've never seen before in order to make a profit -- challenging a company's patents and shorting its stock simultaneously. How exactly does it work, and will it...
SHPG: 253.58 (+3.70), JAZZ: 186.13 (-0.41), ACOR: 33.34 (-1.33)
Will This Hedge Fund Manager Bring Down Your Biotech Stocks?
Selena Maranjian, The Motley Fool - Motley Fool - Sun Apr 19, 12:01PM CDT
Hedge-fund manager Kyle Bass. Image: Insider Monkey Many hedge-fund managers are "activist" ones. They load up on stock in particular companies until they have so many shares that they can put pressure on management to take actions they...
SHPG: 253.58 (+3.70), JAZZ: 186.13 (-0.41), ACOR: 33.34 (-1.33)
4 Big Biopharma Deals We Might See In 2015
Sy Mukherjee - Seeking Alpha - Thu Apr 16, 1:29PM CDT
In 2000, UK-based Glaxo Wellcome joined forces with SmithKline Beecham in a $74 billion merger that birthed the global pharma giant GlaxoSmithKline (NYSE: GSK ). It was, far and away, the biggest biopharma deal of the year. What a difference 14...
BMRN: 121.08 (-0.16), PCYC: 256.98 (-0.77), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72), SGEN: 36.92 (-0.32), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), AZN: 73.35 (+0.65), JAZZ: 186.13 (-0.41), MRK: 57.69 (+0.03), ABBV: 64.52 (+0.91)
Goldman's Monster Q1 Spurred By Megadeals, Volatility
at Investor's Business Daily - Thu Apr 16, 10:32AM CDT
Goldman Sachs (GS) crushed Wall Street's first-quarter expectations, as stock market volatility fueled trading revenue and a string of megadeals boosted advisory fees. The investment banking giant earned $5.94 a share, up 47.8% from a year earlier...
GS: 198.32 (+1.48), JPM: 62.94 (+0.63), C: 53.10 (+0.62), SHPG: 253.58 (+3.70), BAC: 15.74 (+0.24), WFC: 54.67 (+0.39), MS: 37.20 (+0.45)
Cardiomyopathy Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 15, 1:20PM CDT
The report "Cardiomyopathy - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cardiomyopathy. Cardiomyopathy, any cardiac disease process that results in heart failure due to a decrease in the pumping power of the heart or due to an impairment in the filling of the cardiac chambers. Types of Cardiomyopathy are ischemic, dilated, hypertrophic and restrictive Cardiomyopathy. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cardiomyopat...eport.html .
GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), CLDN: 13.59 (-2.77), NVS: 103.45 (-0.62)
Analyzing The FTSE 100 For Opportunities
Nick Mackintosh - at Seeking Alpha - Mon Apr 13, 10:05PM CDT
BTI: 112.59 (+0.32), ARMH: 54.07 (+0.47), SHPG: 253.58 (+3.70)
Goldman's Q1 Seen Lifted By Gyrating Stocks, Big M&A
at Investor's Business Daily - Mon Apr 13, 4:26PM CDT
The volatile stock market and heavier trading volumes should translate into a good first quarter for Goldman Sachs (GS), which also should receive a boost from its financial advisory unit thanks to Q1's strong M&A activity. When it reports results on...
GS: 198.32 (+1.48), JPM: 62.94 (+0.63), SHPG: 253.58 (+3.70), MS: 37.20 (+0.45)
CNS Therapeutics - Global Strategic Business Report 2015-2020
M2 - Mon Apr 13, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ht282w/cns_therapeutics) has announced the addition of the "CNS Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 145 companies including many key and niche players such as: - AbbVie Inc. (USA) - Actavis Plc. (Ireland) - Alkermes Plc. (Ireland) - Amneal Pharmaceuticals, LLC (USA) - Aspen Pharmacare Holdings Limited (Australia) - AstraZeneca Plc (UK) - BIAL Group (Portugal) - Boehringer Ingelheim GmbH (Germany) - Bristol-Myers Squibb (USA) - Dainippon Sumitomo Pharma Co., Ltd. (Japan) - Eisai Co., Ltd. (Japan) - Eli Lilly and Co. (USA) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fabre-Kramer Pharmaceuticals, Inc. (USA) - GlaxoSmithKline (UK) - H. Lundbeck A/S (Denmark) - Johnson & Johnson (USA) - Janssen Pharmaceuticals, Inc. (USA) - Merck & Co., Inc. (USA) - Neurocrine Biosciences, Inc. (USA) - Novartis AG (Switzerland) - Otsuka Pharmaceutical Co., Ltd. (Japan) - Pfizer, Inc. (USA) - Sanofi S.A (France) - Shire Plc (UK) - Sunovion Pharmaceuticals, Inc. (USA) - Takeda Pharmaceutical Co., Ltd. (Japan) - Teva Pharmaceutical Industries Ltd. (Israel) - UCB Group (Belgium) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. NOTEWORTHY MARKET TRENDS, GROWTH DRIVERS & ISSUES 3. MARKET ANALYSIS BY THERAPEUTIC CATEGORIES 4. PRODUCT OVERVIEW 5. PRODUCT INTRODUCTIONS/INNOVATIONS & R&D BREAKTHROUGHS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 145 (including Divisions/Subsidiaries - 172) - The United States (69) - Canada (11) - Japan (14) - Europe (47) - - France (4) - - Germany (9) - - The United Kingdom (11) - - Italy (1) - - Rest of Europe (22) - Asia-Pacific (Excluding Japan) (23) - Middle East (7) - Africa (1) For more information visit http://www.researchandmarkets.com/research/ht...erapeutics
PFE: 34.93 (+0.04), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), ALKS: 62.60 (-0.24), JNJ: 100.43 (+0.13), NBIX: 43.23 (-0.43), SHPG: 253.58 (+3.70), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15), ABBV: 64.52 (+0.91), NVS: 103.45 (-0.62)
Shire's SHP625 Fails in Phase II, FDA Accepts Lifitegrast NDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 4:26PM CDT
Shire plc (SHPG) announced disappointing results from the phase II trial IMAGO on pipeline candidate SHP625 (formerly LUM001).
ACT: 295.22 (+0.69), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), ARQL: 2.11 (-0.03)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 423.57 (+1.46), SPHS: 0.82 (+0.01), ADMS: 17.62 (-0.21), TKMR: 18.38 (-0.14), CBYL: 7.02 (-0.38), HPTX: 45.96 (-0.18), QURE: 26.15 (-1.44), SHPG: 253.58 (+3.70), SRPT: 13.52 (+0.04), HZNP: 30.96 (+0.10), GALE: 1.39 (unch), JUNO: 55.72 (-0.68), ABBV: 64.52 (+0.91), CBMG: 32.14 (+2.21), ARNA: 4.47 (+0.01), EXEL: 3.12 (+0.05), ADXS: 22.18 (+0.10), PTLA: 38.48 (-0.47), BMY: 66.60 (-0.21), OCUL: 25.90 (-0.05), NVO: 56.37 (-0.17), DVA: 83.22 (+0.10), HALO: 16.03 (+0.15), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), ALXN: 188.19 (+1.41), NVS: 103.45 (-0.62)
Critical Alerts For GoPro, Shire, Isis Pharmaceuticals, Whiting Petroleum and athenahealth Released By InvestorsObserver
PR Newswire - Fri Apr 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, SHPG, ISIS, WLL and ATHN.
GPRO: 46.25 (+1.94), WLL: 36.12 (+1.16), ISIS: 66.26 (-0.03), SHPG: 253.58 (+3.70), ATHN: 120.16 (-1.35)
